- Home
- PRG vs AKRO Comparison
PRG vs AKRO Comparison
Compare PRG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- AKRO
- Stock Information
- Founded
- PRG 2020
- AKRO 2017
- Country
- PRG United States
- AKRO United States
- Employees
- PRG N/A
- AKRO N/A
- Industry
- PRG Diversified Commercial Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- PRG Consumer Discretionary
- AKRO Health Care
- Exchange
- PRG Nasdaq
- AKRO Nasdaq
- Market Cap
- PRG 1.4B
- AKRO 3.6B
- IPO Year
- PRG N/A
- AKRO 2019
- Fundamental
- Price
- PRG $35.53
- AKRO $42.85
- Analyst Decision
- PRG Hold
- AKRO Strong Buy
- Analyst Count
- PRG 5
- AKRO 8
- Target Price
- PRG $37.20
- AKRO $80.38
- AVG Volume (30 Days)
- PRG 302.1K
- AKRO 871.2K
- Earning Date
- PRG 10-22-2025
- AKRO 11-07-2025
- Dividend Yield
- PRG 1.46%
- AKRO N/A
- EPS Growth
- PRG 109.72
- AKRO N/A
- EPS
- PRG 5.11
- AKRO N/A
- Revenue
- PRG $2,518,216,000.00
- AKRO N/A
- Revenue This Year
- PRG $1.44
- AKRO N/A
- Revenue Next Year
- PRG $3.56
- AKRO N/A
- P/E Ratio
- PRG $6.96
- AKRO N/A
- Revenue Growth
- PRG 5.17
- AKRO N/A
- 52 Week Low
- PRG $23.50
- AKRO $21.34
- 52 Week High
- PRG $50.28
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- PRG 60.92
- AKRO 35.10
- Support Level
- PRG $34.45
- AKRO $42.56
- Resistance Level
- PRG $36.43
- AKRO $45.44
- Average True Range (ATR)
- PRG 0.78
- AKRO 1.77
- MACD
- PRG -0.07
- AKRO -0.21
- Stochastic Oscillator
- PRG 56.94
- AKRO 14.90
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.